|
1
|
Singh R, Yadav V, Kumar S and Saini N:
MicroRNA-195 inhibits proliferation, invasion and metastasis in
breast cancer cells by targeting FASN HMGCR, ACACA and CYP27B1. Sci
Rep. 5:174542015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eroles P, Tormo E, Pineda B, Espin E and
Lluch A: MicroRNAs in breast cancer: One more turn in regulation.
Curr Drug Targets. 17:1083–1100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura S, Yagata H, Ohno S, Yamaguchi H,
Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K and Suzuki E:
Multi-center study evaluating circulating tumor cells as a
surrogate for response to treatment and overall survival in
metastatic breast cancer. Breast Cancer. 17:199–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gong Y, He T, Yang L, Yang G, Chen Y and
Zhang X: The role of miR-100 in regulating apoptosis of breast
cancer cells. Sci Rep. 5:116502015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muenst S, Däster S, Obermann EC, Droeser
RA, Weber WP, von Holzen U, Gao F, Viehl C, Oertli D and Soysal SD:
Nuclear expression of snail is an independent negative prognostic
factor in human breast cancer. Dis Markers. 35:337–344. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu L, Ju F, Zhao H and Ma X: MicroRNA-134
modulates resistance to doxorubicin in human breast cancer cells by
downregulating ABCC1. Biotechnol Lett. 37:2387–2394. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zielinska HA, Bahl A, Holly JM and Perks
CM: Epithelial-to-mesenchymal transition in breast cancer: A role
for insulin-like growth factor I and insulin-like growth
factor-binding protein 3? Breast Cancer (Dove Med Press). 7:9–19.
2015.PubMed/NCBI
|
|
9
|
Pdel C Monroig, Chen L, Zhang S and Calin
GA: Small molecule compounds targeting miRNAs for cancer therapy.
Adv Drug Deliv Rev. 81:104–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith L, Baxter EW, Chambers PA, Green CA,
Hanby AM, Hughes TA, Nash CE, Millican-Slater RA, Stead LF,
Verghese ET and Speirs V: Down-regulation of miR-92 in breast
epithelial cells and in normal but not tumour fibroblasts
contributes to breast carcinogenesis. PLoS One. 10:e01396982015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fei B and Wu H: MiR-378 inhibits
progression of human gastric cancer MGC-803 cells by targeting
MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Yin B, Wang B, Ma Z, Liu W and Lv
G: MicroRNA-210 promotes proliferation and invasion of peripheral
nerve sheath tumor cells targeting EFNA3. Oncol Res. 21:145–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Misawa A, Katayama R, Koike S, Tomida A,
Watanabe T and Fujita N: AP-1-Dependent miR-21 expression
contributes to chemoresistance in cancer stem cell-like SP cells.
Oncol Res. 19:23–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohdaira H, Sekiguchi M, Miyata K and
Yoshida K: MicroRNA-494 suppresses cell proliferation and induces
senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W
and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer
by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomasetti M, Santarelli L, Neuzil J and
Dong L: MicroRNA regulation of cancer metabolism: Role in tumour
suppression. Mitochondrion. 19:29–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rusek AM, Abba M, Eljaszewicz A, Moniuszko
M, Niklinski J and Allgayer H: MicroRNA modulators of epigenetic
regulation, the tumor microenvironment and the immune system in
lung cancer. Mol Cancer. 14:342015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hurst DR, Edmonds MD and Welch DR:
Metastamir: The field of metastasis-regulatory microRNA is
spreading. Cancer Res. 69:7495–7498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang H, Liu P, Yang L and Xie X, Ye F, Wu
M, Liu X, Chen B, Zhang L and Xie X: miR-185 suppresses tumor
proliferation by directly targeting E2F6 and DNMT1 and indirectly
upregulating BRCA1 in triple-negative breast cancer. Mol Cancer
Ther. 13:3185–3197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pu Q, Huang Y, Lu Y, Peng Y, Zhang J, Feng
G, Wang C, Liu L and Dai Y: Tissue-specific and plasma microRNA
profiles could be promising biomarkers of histological
classification and TNM stage in non-small cell lung cancer. Thorac
Cancer. 7:348–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song J, Bai Z, Zhang J, Meng H, Cai J,
Deng W, Bi J, Ma X and Zhang Z: Serum microRNA-21 levels are
related to tumor size in gastric cancer patients but cannot predict
prognosis. Oncol Lett. 6:1733–1737. 2013.PubMed/NCBI
|
|
23
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Ann Biol Clin (Paris).
68:263–272. 2010.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li
S, Zhou J, Turner J, Lisanti MP, Russell RG, et al: Akt1 governs
breast cancer progression in vivo. Proc Natl Acad Sci USA. 104:pp.
7438–7443. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng Y, Huang Z, Xu Y, Jin J, Zhuo W,
Zhang C, Zhang X, Shen M, Yan X, Wang L, et al: MiR-215 modulates
gastric cancer cell proliferation by targeting RB1. Cancer Lett.
342:27–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu YJ and Fan Y: MiR-215/192 participates
in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li N, Zhang QY, Zou JL, Li ZW, Tian TT,
Dong B, Liu XJ, Ge S, Zhu Y, Gao J and Shen L: miR-215 promotes
malignant progression of gastric cancer by targeting RUNX1.
Oncotarget. 26:4817–4828. 2016.
|
|
29
|
Liang H, Li Y, Luo RY and Shen FJ:
MicroRNA-215 is a potential prognostic marker for cervical cancer.
J Huazhong Univ Sci Technolog Med Sci. 34:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ge G, Zhang W, Niu L, Yan Y, Ren Y and Zou
Y: miR-215 functions as a tumor suppressor in epithelial ovarian
cancer through regulation of the X-chromosome-linked inhibitor of
apoptosis. Oncol Rep. 35:1816–1822. 2016.PubMed/NCBI
|
|
31
|
Li QW, Zhou T, Wang F, Jiang M, Liu CB,
Zhang KR, Zhou Q, Tian Z and Hu KW: MicroRNA-215 functions as a
tumor suppressor and directly targets ZEB2 in human pancreatic
cancer. Genet Mol Res. 14:16133–16145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R
and Zhao C: miR-215 functions as a tumor suppressor and directly
targets ZEB2 in human non-small cell lung cancer. Oncol Lett.
10:1985–1992. 2015.PubMed/NCBI
|
|
33
|
Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y,
Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated
with clinical outcome in breast cancer patients. Med Oncol.
31:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Karaayvaz M, Pal T, Song B, Zhang C,
Georgakopoulos P, Mehmood S, Burke S, Shroyer K and Ju J:
Prognostic significance of miR-215 in colon cancer. Clin Colorectal
Cancer. 10:340–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ge G, Zhang W, Niu L, Yan Y, Ren Y and Zou
Y: miR-215 functions as a tumor suppressor in epithelial ovarian
cancer through regulation of the X-chromosome-linked inhibitor of
apoptosis. Oncol Rep. 35:1816–1822. 2016.PubMed/NCBI
|
|
36
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang B, Hao C, Wang H, Zhang J, Xing R,
Shao J, Li W, Xu N, Lu Y and Liu S: Evaluation of
hepatic-metastasis risk of colorectal cancer upon the protein
signature of PI3K/AKT pathway. J Proteome Res. 7:3507–3515. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang G, Liu Z, Xu H and Yang Q:
miR-409-3p suppresses breast cancer cell growth and invasion by
targeting Akt1. Biochem Biophys Res Commun. 469:189–195. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun M, Wang G, Paciga JE, Feldman RI, Yuan
ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng
JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers
and its constitutive activation is required for oncogenic
transformation in NIH3T3 cells. Am J Pathol. 159:431–437. 2001.
View Article : Google Scholar : PubMed/NCBI
|
